| $385M | ||
| $337M | ||
| $100M | ||
| $87M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $729,773 | 10 | 100 |
| Chu Yu-Waye | Chief Medical Officer | 0 | $0 | 1 | $2,411 | $-2,411 |
| ROWLAND LLOYD A | General Counsel | 0 | $0 | 1 | $6,112 | $-6,112 |
| Ogden Christopher | Chief Financial Officer | 0 | $0 | 3 | $38,503 | $-38,503 |
| BELVIN MARCIA | SVP, Chief Scientific Officer | 0 | $0 | 2 | $49,022 | $-49,022 |
| McCarthy Sean A. | CEO | 0 | $0 | 3 | $633,726 | $-633,726 |
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Over the last 12 months, insiders at CytomX Therapeutics, Inc. have bought $0 and sold $729,773 worth of CytomX Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at CytomX Therapeutics, Inc. have bought $7,750 and sold $497,231 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $7,750 was made by Jones Elaine V (director) on 2023‑03‑29.
| 2025-11-06 | Sale | McCarthy Sean A. | CEO | 101,793 0.0785% | $4.54 | $461,906 | -5.13% | |
| 2025-06-16 | Sale | McCarthy Sean A. | CEO | 55,511 0.0385% | $2.69 | $149,264 | -2.44% | |
| 2025-06-16 | Sale | BELVIN MARCIA | SVP, Chief Scientific Officer | 13,884 0.0096% | $2.69 | $37,334 | -2.44% | |
| 2025-06-16 | Sale | Ogden Christopher | Chief Financial Officer | 10,614 0.0074% | $2.69 | $28,540 | -2.44% | |
| 2025-06-13 | Sale | Ogden Christopher | Chief Financial Officer | 1,641 0.0011% | $2.95 | $4,841 | -12.73% | |
| 2025-03-18 | Sale | McCarthy Sean A. | CEO | 37,656 0.0466% | $0.60 | $22,556 | +289.27% | |
| 2025-03-18 | Sale | BELVIN MARCIA | SVP, Chief Scientific Officer | 19,512 0.0242% | $0.60 | $11,688 | +289.27% | |
| 2025-03-18 | Sale | Ogden Christopher | Chief Financial Officer | 8,551 0.0106% | $0.60 | $5,122 | +289.27% | |
| 2025-03-18 | Sale | Chu Yu-Waye | Chief Medical Officer | 4,025 0.005% | $0.60 | $2,411 | +289.27% | |
| 2025-03-18 | Sale | ROWLAND LLOYD A | General Counsel | 10,203 0.0126% | $0.60 | $6,112 | +289.27% | |
| 2024-08-20 | Sale | McCarthy Sean A. | CEO | 13,898 0.0176% | $1.23 | $17,082 | -10.08% | |
| 2024-08-20 | Sale | BELVIN MARCIA | SVP, Chief Scientific Officer | 4,181 0.0053% | $1.23 | $5,139 | -10.08% | |
| 2024-08-20 | Sale | ROWLAND LLOYD A | General Counsel | 4,181 0.0053% | $1.23 | $5,139 | -10.08% | |
| 2024-08-20 | Sale | Landau Jeffrey B | Chief Business Officer | 4,181 0.0053% | $1.23 | $5,139 | -10.08% | |
| 2024-08-20 | Sale | Ogden Christopher | Chief Financial Officer | 1,984 0.0025% | $1.23 | $2,439 | -10.08% | |
| 2024-03-19 | Sale | McCarthy Sean A. | CEO | 20,223 0.0286% | $2.09 | $42,175 | -45.64% | |
| 2024-03-19 | Sale | BELVIN MARCIA | SVP, Chief Scientific Officer | 12,795 0.0181% | $2.09 | $26,684 | -45.64% | |
| 2024-03-19 | Sale | ROWLAND LLOYD A | General Counsel | 5,268 0.0074% | $2.09 | $10,986 | -45.64% | |
| 2024-03-19 | Sale | Landau Jeffrey B | Chief Business Officer | 6,562 0.0093% | $2.09 | $13,685 | -45.64% | |
| 2024-03-19 | Sale | Ogden Christopher | SVP, Finance and Accounting | 2,971 0.0042% | $2.09 | $6,196 | -45.64% |
| McCarthy Sean A. | CEO | 987891 0.5833% | $4.03M | 0 | 37 | |
| BELVIN MARCIA | SVP, Chief Scientific Officer | 272252 0.1607% | $1.11M | 0 | 6 | |
| Ogden Christopher | Chief Financial Officer | 226271 0.1336% | $923,185.68 | 0 | 7 | |
| Chu Yu-Waye | Chief Medical Officer | 135725 0.0801% | $553,758.00 | 0 | 1 | |
| ROWLAND LLOYD A | General Counsel | 120594 0.0712% | $492,023.52 | 1 | 7 | <0.0001% |
| THIRD ROCK VENTURES LP | 10 percent owner | 5170348 3.0527% | $21.1M | 0 | 2 | |
| Canaan IX L.P. | director | 3644381 2.1517% | $14.87M | 0 | 29 | |
| SHANNON TIMOTHY M | director | 3244381 1.9156% | $13.24M | 0 | 29 | |
| Flynn James E | 10 percent owner | 671024 0.3962% | $2.74M | 1 | 0 | <0.0001% |
| GLUCK FREDERICK W | director | 271643 0.1604% | $1.11M | 1 | 8 | <0.0001% |
| Landau Jeffrey B | Chief Business Officer | 119056 0.0703% | $485,748.48 | 0 | 6 | |
| Peterson Amy C. | EVP, Chief Development Officer | 58433 0.0345% | $238,406.64 | 0 | 2 | |
| Campoy Carlos | Chief Financial Officer | 38224 0.0226% | $155,953.92 | 0 | 2 | |
| HANNAH ALISON L. | Chief Medical Officer | 31898 0.0188% | $130,143.84 | 0 | 1 | |
| STARR KEVIN P | 10 percent owner | 31419 0.0186% | $128,189.52 | 0 | 1 | |
| HUMPHREY RACHEL | Chief Medical Officer | 30234 0.0179% | $123,354.72 | 0 | 2 | |
| TEPPER ROBERT I | 10 percent owner | 29516 0.0174% | $120,425.28 | 0 | 3 | |
| Kavanaugh William Michael | CSO, Head Res.&Non-Clin. Dev. | 13917 0.0082% | $56,781.36 | 1 | 1 | <0.0001% |
| Goeltz II Robert C. | Chief Financial Officer | 9789 0.0058% | $39,939.12 | 0 | 1 | |
| RAY DEBANJAN | Chief Financial Officer | 5928 0.0035% | $24,186.24 | 0 | 19 | |
| Jones Elaine V | director | 5142 0.003% | $20,979.36 | 1 | 0 | +0.98% |
| LADD CYNTHIA J | Senior VP and General Counsel | 3000 0.0018% | $12,240.00 | 1 | 0 | <0.0001% |
| Exter Neil | director | 0 0% | $0 | 0 | 2 |
$100,473,344 | 83 | 9.53% | $657.64M | |
$5,911,307 | 70 | -1.38% | $641.71M | |
$35,092,436 | 31 | 38.62% | $570.05M | |
$41,446,394 | 27 | 12.91% | $766.11M | |
$169,638,586 | 22 | 30.82% | $729.72M | |
$3,556,951 | 18 | 9.64% | $753.86M | |
$109,488,423 | 15 | 56.69% | $600.74M | |
$92,357,691 | 12 | 87.24% | $821.72M | |
$75,069,528 | 10 | 19.77% | $723.22M | |
$1,229,070 | 10 | 23.53% | $781.96M | |
$140,543,039 | 10 | 0.77% | $692.22M | |
$38,624,786 | 9 | 1.26% | $625.02M | |
$94,000,000 | 7 | -20.84% | $684.82M | |
$1,229,547 | 7 | 11.98% | $810.71M | |
CytomX Therapeutics, Inc. (CTMX) | $15,652,720 | 6 | -4.77% | $691.03M |
$51,588,185 | 5 | 19.18% | $748.95M | |
$40,959,889 | 5 | -1.88% | $570.87M | |
$9,999,990 | 2 | 25.53% | $663.45M | |
$3,850,000 | 1 | -51.32% | $657.04M |
| Increased Positions | 60 | +65.93% | 30M | +22.87% |
| Decreased Positions | 37 | -40.66% | 26M | -19.81% |
| New Positions | 31 | New | 9M | New |
| Sold Out Positions | 12 | Sold Out | 12M | Sold Out |
| Total Postitions | 114 | +25.27% | 137M | +3.06% |
| Vr Adviser, Llc | $66,603.00 | 9.21% | 15.56M | +2M | +11.39% | 2025-09-30 |
| Fmr Llc | $65,896.00 | 9.11% | 15.4M | +6M | +66.65% | 2025-09-30 |
| Tang Capital Management Llc | $47,361.00 | 6.55% | 11.07M | 0 | 0% | 2025-09-30 |
| Perceptive Advisors Llc | $41,431.00 | 5.73% | 9.68M | +3M | +38.41% | 2025-09-30 |
| Vanguard Group Inc | $38,297.00 | 5.3% | 8.95M | -431,987 | -4.61% | 2025-09-30 |
| Orbimed Advisors Llc | $36,215.00 | 5.01% | 8.46M | 0 | 0% | 2025-09-30 |
| Commodore Capital Lp | $32,923.00 | 4.55% | 7.69M | 0 | 0% | 2025-09-30 |
| Baker Bros. Advisors Lp | $18,194.00 | 2.52% | 4.25M | +766,600 | +22% | 2025-09-30 |
| Point72 Asset Management, L.P. | $17,414.00 | 2.41% | 4.07M | -4M | -49.67% | 2025-09-30 |
| Adar1 Capital Management, Llc | $17,314.00 | 2.39% | 4.05M | +964,000 | +31.28% | 2025-09-30 |